Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Melanoma Drugs Market Forecast 2014-2024 : GENTA
LONDON, December 12, 2014 /PRNewswire/ --
http://www.prnewswire.com/news-releases/melanoma-drugs-market-forecast-2014-2024-285606201.html
Why converting the notes into common shares?If the company was over, why converting?!
In the aggregate, the Reporting Persons may be deemed to beneficially own 662,117,262 shares of the Common Stock of the Issuer, representing approximately 9.999% of such class of securities, which is comprised of 662,117,262 shares underlying $662,117.26 of Notes. The beneficial ownership of each Reporting Person is as follows: (i) Fund beneficially owns 342,540,949 shares of the Common Stock of the Issuer, representing approximately 5.4% of such class of securities, which is comprised of 342,540,949 shares underlying $342,540.95 of Notes. In the aggregate the Fund owns $229,011.58 principal amount of the C Notes, and $189,371.54 principal amount of the D Notes, $148,400.00 principal amount of the G Notes, $16,800.00 principal amount of the H Notes, $232,103.00 principal amount of the I Notes, $300,000.00 principal amount of the E Notes, $140,000.00 principal amount of G Note Warrant A and $280,000.00 principal amount of G Note Warrant B and (ii) Capital, as the investment adviser and sole general partner of the Fund and investment adviser to an account owned by a separate investment vehicle which holds shares of the Issuer's Common Stock, and Mr. Kolchinsky as the manager of Capital, each beneficially own 662,117,262 shares of the Common Stock of the Issuer, representing approximately 9.999% of such class of securities, which is comprised of 662,117,262 shares underlying $662,117.26 of Notes. The percentage of Common Stock beneficially owned by each Reporting Person is based on a total of 5,959,717,543 shares of Common Stock of the Issuer outstanding per the Issuer’s Definitive Proxy Statement as filed with the SEC on June 22, 2012 plus shares of Common Stock issuable upon conversion of Notes.
The Fund has the power to vote and dispose of the shares of Common Stock beneficially owned by such entity (as described above). Capital, as the investment adviser and sole general partner of the Fund and as the investment adviser to an account owned by a separate investment vehicle which holds shares of the Issuer’s Common Stock, has the sole authority to vote and dispose of all of the shares of Common Stock reported in this Schedule 13G. The Manager, by virtue of his position as manager of Capital, has the sole authority to vote and dispose of all of the shares of Common Stock reported in this Schedule 13G.
Any public result of this trial?
https://clinicaltrials.gov/ct2/show/results/NCT01064713
Tesetaxel
Alternative Names: DJ-927
Latest Information Update: 11 Feb 2015
http://adisinsight.springer.com/drugs/800016475
Ex-Genta Exec Settles SEC Insider Suit Over Melanoma Drug
http://www.law360.com/articles/530218/ex-genta-exec-settles-sec-insider-suit-over-melanoma-drug
Yes many years I'm doing this.
As of now I'm sure you have come to know about the MANY years I'm doing what I do...
Have I helped you in particular with Rich Pharma? ??....
Cause without you even knowing you sure helped me:)
Thanks and please keep us informed.
An administrative proceeding is a non-judicial determination of fault or wrongdoing and may include, in some cases, penalties of various forms. They are typically conducted by government or military institutions.
In a military setting, a "Captain's Mast", held by a commanding officer of a U.S. Navy unit is one such administrative proceeding. As a consequence of the proceeding, the commander may impose non-judicial punishment upon members of the command.
Various other administrations of government (for example, a department regulating motor vehicles, air pollution, forestry practices, or real estate sales agents) may impose fines or revocation of permits or licenses upon persons or corporations for acts of commission or omission found to be violating operating, permitting, reporting, or other rules. Such rules are typically formulated in the specific by the administrative authority under general authority established and limited by statute.
There may be additional paths of judicial appeal in some cases, provided all appeal paths internal to the administrative group have been exhausted., In general, such appeals are usually not based on the determination of fact (unless relevant evidence was not allowed to be presented), but rather on some legal theory that the administrative body exceeded its statutory authority, or that the administrative body did not follow its own established rules of procedure, or that the authorising statute itself or the subsequently derived rules are defective in some way, for example by being an unconstitutional infringement of some constitutional right. In these cases the case may be remanded to the authority for further examination and determination under the new rules established by the court or the administrative decision may be declared null and void with prejudice.
http://en.wikipedia.org/wiki/Administrative_proceeding
What is Admin Proceeding and where can you find this information?
"Admin Proceeding".Not yet finished
Yep, but if you played it right, there was money to be made at certain times during the scam
One, if not the biggest Dilution turd ever )-
Well, it's official.....GNTA is officially done.
Happy Thanksgiving everyone!~
GNTAQ revoked:
Sept 4 SEC Admin Proceeding:
http://www.sec.gov/litigation/admin/2014/34-72981.pdf
Nov. 24 revocation Order:
http://www.sec.gov/litigation/admin/2014/34-73673.pdf
Have somebody read the detailed describtion of the Genta case parties before the court? I have found a site, where the parties involved read the following:
Genta Incorporated
200 Connell Drive
Berkeley Heights, NJ 07922
UNION-NJ
Tax ID / EIN: xx-xxx6866
aka Genta Development Ltd.
Source: http://business-bankruptcies.com/cases/genta-incorporated
Is the Genta Development Ltd., a British business entity, also in bancrupty before the Delaware court, or is the US Genta Company now under direction of Genta Development Ltd.?
I know from former DD, that Genta has a british subsidary, which is responsible for all paper works regarding the submission and market approvals for drugs developed by Genta, regarding the European Medicinal Agency.
No decision yet. I don't know either.
So hopefully the case comes back to the judges desk. He probably also has to manage the latest hearings of deptors and trustees.
i dont know, the last transaction date is 07.22.2014, also not so far.
These fees are related to the patent application and the patent examination processes. Patents only has to do with the patent office, not with the court and the pending chapter 7. Chapter 7 is decided at the bancruptcy court in Delaware. What reasons are hindering the court, to announce a decision about the Genta case?
fees allready paid.
you can find all transactions here:
http://portal.uspto.gov/pair/PublicPair
Call the trustees and tell them, they have to pay the outstanding court fees, so that the judge will make a decision about chapter 7.
Yes, all about Taxane compunds was back to Genta.
and now?:)
Yes, thank you indesdefilia, I noticed it, especially on the key patents on Tesetaxel. That also means, that investors like GFV LLC transfers the right back to Genta. These investors hold a strong position in Genta, and this might indicate, they know what Genta does or should do with these patents.
Have you seen that a couple of patents went back to Genta ordered by Judge?just waiting what will happen
The inventors, now assignors, of course know what this patent is about. Warrel is now at Relburn, and there he is in a position to decide about future programs.
Might be a key patent, in the case they get Tesetaxel through. Tesetaxel itself is very useful and inhibits cancer grow in a special way.
I have no idea, if this statement, "3-6 weeks", is a reliable one. But I agree with you, that probably something different occured with the case, when it is so much delayed, compared to the normal cases.
Back to Genta! 07.22.2014
nited States Patent 8,785,669
Thottathil , et al. July 22, 2014
Taxane compounds, compositions and methods
Abstract
The present invention provides a method for the preparation of orally available pentacyclic taxane compounds, as well as intermediates useful in their preparation.
Inventors: Thottathil; John K. (Mundelein, IL), Warrell, Jr.; Raymond P. (Westfield, NJ)
Applicant:
Name City State Country Type
Thottathil; John K.
Warrell, Jr.; Raymond P.
Mundelein
Westfield
IL
NJ
US
US
Assignee: GFV, LLC (San Diego, CA)
Family ID: 45400196
Appl. No.: 13/170,830
Filed: June 28, 2011
NO, it doesnt matter.
"Typically, a Chapter 7 bankruptcy case is relatively quick to complete. Your bankruptcy case could be completed and discharged within 3-6 months of filing bankruptcy"
also, something else was happend.
Hhhm, the judge may order this, after application of one creditor. Warrel has made claims against his company after Genta went in chapter 7, therefor Warrel is a creditor. The new assignors, also the inventors, know very well the impact of the patent, when Genta goes to market with tesetaxel.
Bureocracy is working slowly. Maybe the files could not be found, or the case has not the highest priority. I don't know either. Maybe the judge is waiting for more information from the trustees?
USPTO Requests Reconsideration In Patent Term Adjustment Tolling Case
Review Of Patent Term Adjustment Awards
The PTA statute (35 U.S.C. § 154) provides two different avenues of review of a PTA award.
http://www.pharmapatentsblog.com/2012/04/03/uspto-requests-reconsideration-in-patent-term-adjustment-tolling-case/
FINE FINE FINE!
One!!.. of the application nr.20120220634 BACK TO GENTA BY LAW!!
http://www.plainsite.org/patents/assignment.html?id=6303746
AND THEN...
USPTO Assignment
http://portal.uspto.gov/pair/PublicPair
looking for TRANSACTION HISTORY
04-15-2015!!!
PATENT ISSUE DATE USED IN PTA CALCULATION
Did you see that the Patents nr.
-A1Application Publication No. 20120004429
-A1Application Publication No. 20120220634
in a first time in 2013 given to Heron, were back to Genta in Februar and April 2014 when the BK7 was going on?
maybe the Judge ordered this.
"Typically, a Chapter 7 bankruptcy case is relatively quick to complete. Your bankruptcy case could be completed and discharged within 3-6 months of filing bankruptcy"
what the Judge is waiting for?i dont understand
Is Ray & Lorretta still eating lobster at there local restaurant ?
i guess so .....
biggest scam ever this one IMO.
Maybe they expand their studies with Genasense again?
I agree, but we have noticed that already before. The thing which is most interesting to me, that someone feels responsilbe to update the status of the studies. Probably one of the trustees who oversees the progress of the studies, because he's in charge of leading the company while in chapter 7.
Hope, i get my new Genta shares very soon
Its more important that studies are going on
Yes, they always want to try to get the best results out of Genasense. Sure it works.
Yes, of course no results are published on clinicaltrails.gov . Results normally are published through an announcement by the the clinical study team leader on a conference, in a scientific publication, or sometimes also through the website of a company, which wants to promote their business with the drug. Don't expect too much changes. Results probably will be in the range of what was achieved in prior studies. So we can overall expect good results, which will have a positive impact on the FDA regulations.
Very interesting, thank you. But the November date is just confirmation on an update. So it seems, that someone looks after the the advanced status of the studies. The primary endpoint of the study was October 2014, and after this someone updated the data at clinicaltrails.gov.
That makes it a bit more interesting now.
Houston, TX – M D Anderson Clinical Trials
Genasense is going on as well at the hospital.
http://trackingmelanoma.wordpress.com/major-melanoma-centers-clinical-trials/m-d-anderson/
No Study Results Posted on ClinicalTrials.gov for this Study
Studies are going on!Phase II Study of Tesetaxel in Metastatic Melanoma COMPLETED IN NOVEMBER 2014!!
http://clinicaltrials.gov/ct2/show/NCT01064713?term=genta+incorporated&rank=28
Infos, if any, should be released from the trustees, who oversee the current status.
Hi inesdefilia, unfortunately pps is fixed in concrete.
Followers
|
287
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
58465
|
Created
|
02/12/02
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |